Collaboration, License and Other Arrangements - Schedule of Credits Recognized in Condensed Consolidated Statements of Income (Loss) (Details) - USD ($) $ in Millions |
3 Months Ended | 6 Months Ended | ||
|---|---|---|---|---|
Jun. 30, 2026 |
Jun. 30, 2025 |
Jun. 30, 2026 |
Jun. 30, 2025 |
|
| Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] | ||||
| Cost of sales | $ 489.2 | $ 407.5 | $ 882.0 | $ 770.5 |
| Research and development expenses | 993.8 | 978.4 | 1,955.4 | 1,958.1 |
| Acquired in-process research and development expenses | 21.4 | 2.2 | 21.9 | 22.0 |
| CRISPR JDCA | ||||
| Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] | ||||
| Cost of sales | 21.8 | 30.1 | 44.9 | 66.3 |
| Research and development expenses | 14.4 | 15.1 | 30.5 | 31.1 |
| Acquired in-process research and development expenses | $ 0.0 | $ 0.0 | $ 0.0 | $ 12.5 |
| X | ||||||||||
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities. Reference 1: http://www.xbrl.org/2003/role/exampleRef
|
| X | ||||||||||
- Definition Amount of writeoff for research and development asset acquired in transaction other than business combination or from joint venture formation or both. Includes, but is not limited to, software to be sold, leased, or marketed. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition Amount of expense for research and development. Excludes cost for computer software product to be sold, leased, or otherwise marketed, writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both, and write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity. Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
|
| X | ||||||||||
- Details
|